{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:00:08Z","timestamp":1787497208307,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.juro.2008.04.012","type":"journal-article","created":{"date-parts":[[2008,6,13]],"date-time":"2008-06-13T11:20:18Z","timestamp":1213356018000},"page":"565-570","source":"Crossref","is-referenced-by-count":106,"title":["Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy Before Radical Prostatectomy for Patients With High Risk Localized Prostate Cancer"],"prefix":"10.1097","volume":"180","author":[{"given":"Kim N.","family":"Chi","sequence":"first","affiliation":[{"name":"Prostate Centre at Vancouver General Hospital, BC Cancer Agency, Vancouver Centre and the Canadian Uro-Oncology Group, Vancouver, British Columbia, the London Health Sciences Centre, London, Sunnybrook Regional Cancer Centre and Princess Margaret Hospital, Toronto, Ontario, University of Montreal, Montreal, and the Tom Baker Cancer Centre, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Chin","sequence":"additional","affiliation":[{"name":"Prostate Centre at Vancouver General Hospital, BC Cancer Agency, Vancouver Centre and the Canadian Uro-Oncology Group, Vancouver, British Columbia, the London Health Sciences Centre, London, Sunnybrook Regional Cancer Centre and Princess Margaret Hospital, Toronto, Ontario, University of Montreal, Montreal, and the Tom Baker Cancer Centre, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Winquist","sequence":"additional","affiliation":[{"name":"Prostate Centre at Vancouver General Hospital, BC Cancer Agency, Vancouver Centre and the Canadian Uro-Oncology Group, Vancouver, British Columbia, the London Health Sciences Centre, London, Sunnybrook Regional Cancer Centre and Princess Margaret Hospital, Toronto, Ontario, University of Montreal, Montreal, and the Tom Baker Cancer Centre, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Klotz","sequence":"additional","affiliation":[{"name":"Prostate Centre at Vancouver General Hospital, BC Cancer Agency, Vancouver Centre and the Canadian Uro-Oncology Group, Vancouver, British Columbia, the London Health Sciences Centre, London, Sunnybrook Regional Cancer Centre and Princess Margaret Hospital, Toronto, Ontario, University of Montreal, Montreal, and the Tom Baker Cancer Centre, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[{"name":"Prostate Centre at Vancouver General Hospital, BC Cancer Agency, Vancouver Centre and the Canadian Uro-Oncology Group, Vancouver, British Columbia, the London Health Sciences Centre, London, Sunnybrook Regional Cancer Centre and Princess Margaret Hospital, Toronto, Ontario, University of Montreal, Montreal, and the Tom Baker Cancer Centre, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Gleave","sequence":"additional","affiliation":[{"name":"Prostate Centre at Vancouver General Hospital, BC Cancer Agency, Vancouver Centre and the Canadian Uro-Oncology Group, Vancouver, British Columbia, the London Health Sciences Centre, London, Sunnybrook Regional Cancer Centre and Princess Margaret Hospital, Toronto, Ontario, University of Montreal, Montreal, and the Tom Baker Cancer Centre, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2008.04.012_bib1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics, 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.juro.2008.04.012_bib2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2008.04.012_bib3","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0022-5347(05)65971-X","article-title":"Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects","volume":"166","author":"Gleave","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2008.04.012_bib4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0090-4295(98)00616-5","article-title":"CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group","volume":"53","author":"Klotz","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.juro.2008.04.012_bib5","first-page":"179","article-title":"Randomized comparative study of 3 vs 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: 3 year PSA recurrence rates","volume":"169","author":"Gleave","year":"2003","journal-title":"J Urol, suppl."},{"key":"10.1016\/j.juro.2008.04.012_bib6","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1158\/0008-5472.CAN-03-3998","article-title":"Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer","volume":"64","author":"Rocchi","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.juro.2008.04.012_bib7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1046\/j.1464-410x.2000.00894.x","article-title":"Adjuvant mitozantrone chemotherapy in advanced prostate cancer","volume":"86","author":"Wang","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2008.04.012_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1159\/000473791","article-title":"Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation","volume":"29","author":"Schmidt","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2008.04.012_bib9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2008.04.012_bib10","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1158\/1078-0432.CCR-04-2140","article-title":"Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer","volume":"11","author":"Eigl","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2008.04.012_bib11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0022-5347(01)65645-3","article-title":"Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer","volume":"156","author":"Goldenberg","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2008.04.012_bib12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1023\/A:1012258723075","article-title":"Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer","volume":"12","author":"Beer","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.juro.2008.04.012_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.juro.2008.04.012_bib14","doi-asserted-by":"crossref","first-page":"8186","DOI":"10.1200\/JCO.2005.03.3068","article-title":"High-risk localized prostate cancer: a case for early chemotherapy","volume":"23","author":"Gleave","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2008.04.012_bib15","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.urology.2004.01.040","article-title":"Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer","volume":"63","author":"Dreicer","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.juro.2008.04.012_bib16","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-05-0299","article-title":"Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer","volume":"11","author":"Febbo","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2008.04.012_bib17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1464-410X.2007.06760.x","article-title":"Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer","volume":"100","author":"Prayer-Galetti","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2008.04.012_bib18","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1097\/01.ju.0000057795.97626.66","article-title":"Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails","volume":"169","author":"Kassouf","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2008.04.012_bib19","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1097\/01.ju.0000091100.83725.51","article-title":"Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens","volume":"170","author":"Eastham","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2008.04.012_bib20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/01.ju.0000108122.36893.5a","article-title":"Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I\/II study","volume":"171","author":"Konety","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2008.04.012_bib21","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0022-5347(01)64963-2","article-title":"Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate","volume":"157","author":"Smith","year":"1997","journal-title":"J Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534708009415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534708009415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2008.04.012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T21:16:43Z","timestamp":1651180603000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2008.04.012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1016\/j.juro.2008.04.012"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2008.04.012","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}